Summit Creek Advisors LLC Makes New $2.41 Million Investment in LifeStance Health Group, Inc. $LFST

Summit Creek Advisors LLC purchased a new position in LifeStance Health Group, Inc. (NASDAQ:LFST) in the 3rd quarter, HoldingsChannel reports. The institutional investor purchased 200,147 shares of the company’s stock, valued at approximately $2,408,000.

Several other large investors have also recently made changes to their positions in LFST. BlackRock Inc. purchased a new stake in shares of LifeStance Health Group during the 2nd quarter worth $389,293,000. Dimensional Fund Advisors LP boosted its position in LifeStance Health Group by 16.4% during the first quarter. Dimensional Fund Advisors LP now owns 10,367,680 shares of the company’s stock valued at $66,038,000 after purchasing an additional 1,461,215 shares in the last quarter. Jennison Associates LLC grew its stake in LifeStance Health Group by 38.5% in the first quarter. Jennison Associates LLC now owns 10,228,801 shares of the company’s stock valued at $65,157,000 after purchasing an additional 2,843,388 shares during the last quarter. Wellington Management Group LLP purchased a new position in LifeStance Health Group in the second quarter valued at about $30,881,000. Finally, Bank of America Corp DE grew its stake in LifeStance Health Group by 165.0% in the first quarter. Bank of America Corp DE now owns 1,994,027 shares of the company’s stock valued at $12,702,000 after purchasing an additional 1,241,475 shares during the last quarter. 85.50% of the stock is owned by institutional investors.

LifeStance Health Group News Summary

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: LifeStance reported Q3 adjusted earnings of $0.06 per share, ahead of estimates, and revenue of $455.9 million versus forecasts of about $431.6 million. Revenue grew 25.3% year over year, and the company raised its full-year outlook—evidence of stronger-than-expected performance. LifeStance Q3 results and outlook
• Positive Sentiment: Analysts raised their targets and maintained bullish ratings: KeyCorp lifted its target to $17 with an “overweight” rating, Canaccord Genuity raised its target to $16 with a “buy” rating, and BTIG increased its target to $20, also with a “buy” rating. These revisions signal greater optimism about potential upside. KeyCorp rating Canaccord Genuity rating BTIG target increase
• Neutral Sentiment: Coverage noted LFST reached a 52-week high and highlighted its momentum, though those signals alone do not establish whether further gains are sustainable. Zacks coverage of LFST’s high

Insider Activity at LifeStance Health Group

In other LifeStance Health Group news, COO Lisa K. Miller sold 47,912 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $10.85, for a total value of $519,845.20. Following the sale, the chief operating officer owned 281,289 shares in the company, valued at approximately $3,051,985.65. This represents a 14.55% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CTO Vukasin Paunovich sold 44,394 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $10.85, for a total transaction of $481,674.90. Following the sale, the chief technology officer directly owned 247,446 shares in the company, valued at $2,684,789.10. The trade was a 15.21% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 13,777,580 shares of company stock worth $146,433,781. 3.50% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages have commented on LFST. Wall Street Zen downgraded shares of LifeStance Health Group from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 5th. Barclays raised their price target on shares of LifeStance Health Group from $13.00 to $15.00 and gave the company an “overweight” rating in a report on Thursday, September 10th. KeyCorp lifted their price objective on shares of LifeStance Health Group from $15.00 to $17.00 and gave the stock an “overweight” rating in a research report on Friday. Canaccord Genuity Group boosted their price objective on shares of LifeStance Health Group from $15.00 to $16.00 and gave the stock a “buy” rating in a research note on Friday. Finally, Weiss Ratings raised shares of LifeStance Health Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $13.75.

LifeStance Health Group Stock Up 2.5%

LFST stock opened at $13.77 on Friday. The firm’s fifty day simple moving average is $12.62 and its 200-day simple moving average is $9.49. The company has a market capitalization of $5.26 billion, a P/E ratio of 72.48 and a beta of 1.35. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.44 and a quick ratio of 1.38. LifeStance Health Group, Inc. has a 12 month low of $5.87 and a 12 month high of $15.66.

LifeStance Health Group (NASDAQ:LFST) last announced its quarterly earnings results on Thursday, November 5th. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.02. The company had revenue of $455.86 million for the quarter, compared to the consensus estimate of $431.59 million. LifeStance Health Group had a return on equity of 4.82% and a net margin of 4.29%. LifeStance Health Group’s quarterly revenue was up 25.3% compared to the same quarter last year. As a group, equities research analysts forecast that LifeStance Health Group, Inc. will post 0.17 earnings per share for the current year.

LifeStance Health Group Profile

LifeStance Health Group, Inc is a provider of outpatient behavioral health services in the United States. Through a network of clinicians and care centers, the company offers mental health care through in-person appointments and telehealth visits.

LifeStance’s services include individual, couples and family therapy; psychiatric evaluation and medication management; psychological and neuropsychological testing; and treatment for conditions such as depression, anxiety, attention-deficit/hyperactivity disorder, bipolar disorder, post-traumatic stress disorder and other behavioral health concerns.